MiMedx Reports 13.1% Net Sales Increase to $98.6 Million in Q2 2025

MiMedx Group, Inc. reported a net sales increase of 13.1% for the second quarter of 2025, reaching $98.6 million compared to $87.2 million in the same period last year. The growth was driven by a 12% rise in Wound product sales, totaling $64.5 million, and a 15.1% increase in Surgical product sales, which amounted to $34.1 million. Despite the revenue growth, the company experienced a decline in net income from continuing operations, which fell to $9.6 million, or $0.07 per share, down from $17.6 million, or $0.12 per share, in the prior year quarter.

For the first half of 2025, MiMedx reported total net sales of $186.8 million, an 8.7% increase from $171.9 million in the same period of 2024. The Wound product line saw a modest increase of 5.2%, while the Surgical segment experienced a more significant growth of 15.6%. The company's gross profit margin decreased to 81.1% from 83.8% year-over-year, attributed to higher production costs and amortization of intangible assets related to recent acquisitions.

Operationally, MiMedx's total current assets rose to $220.9 million as of June 30, 2025, compared to $191.9 million at the end of 2024. The company also reported a cash balance of $118.9 million, reflecting a $50 million increase from the previous year. The total liabilities increased slightly to $74.5 million, with long-term debt standing at $18.5 million. The company’s employee headcount remained stable, supporting its operational needs as it continues to expand its product offerings.

Strategically, MiMedx has focused on broadening its product portfolio, including the recent acquisition of exclusive rights to market a collagen particulate xenograft product through its agreement with TELA Bio, Inc. The company is also navigating potential changes in reimbursement policies from the Centers for Medicare and Medicaid Services, which could impact its financial performance starting January 1, 2026. MiMedx is optimistic about its growth trajectory, emphasizing its commitment to innovation and market expansion, particularly in the U.S. and emerging international markets.

Looking ahead, MiMedx anticipates continued growth driven by its expanding product lines and strategic initiatives. The company plans to leverage its cash reserves and credit facilities to support ongoing operations and potential acquisitions, aiming to enhance its market position in the wound care and surgical sectors.